COMPARISON OF INTRAVITREAL INJECTION OF TRIAMCINOLONE ACETONIDE AND BEVACIZUIVIAB AS A PRIMARY TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA
|Full paper||Not Available|
INTRODUCTION: Dintwtic retinopathy is the leading cause of blindness in patients aged 20-74 years in the United States, Chew and Ferris (2001). Diabetic macular edema (DME) is a manifestation of diabetic rednopathy that produces loss of central vision. Klein, et aL, (1984). Two different subtypes of DME are recognized. Focal macuirir edema, and diffuse macular edema, Ciardella, et aL, (2004). intrauitreal injection has been proposed as a new technique in the treatment, Jonas, et al., (2003). Triamcinolone Acetonide (TA) is a synthetic glucocorticoid analog with marked anti-inflammatory action, used to take the advantage of its antiedematous effect, Jonas and SOfker (2001). Anti-vascular endothelial growth factor (VEGF) therapy has probably been one of the most promising breakthroughs in medical retina treatment Brwon, et aL, (2006). Bevacizumab, a full length monoclonal antibody binding all isoforms of VEGF, Michels, et al., (2005) and Moshfeght et al., (2006) . Bevacizurnab is rapidly becoming one of the leading treatments for neovascular diseases, Fung, et aL, (2006) and Jorge, et aL, (2006) .